1.In vitro Screening of Ginkgolic Acids for Antiparasitic Activity against Cryptosporidium andersoni.
Chidiebere E UGWU ; Yan Yan JIANG ; Liang WU ; Yu Xin XU ; Jian Hai YIN ; Li Ping DUAN ; Sheng Xia CHEN ; Hua LIU ; Wei PAN ; Hong QUAN ; Yu Juan SHEN ; Jian Ping CAO
Biomedical and Environmental Sciences 2019;32(4):300-303
2.Study on transdermal characteristics of compound Nanxing pain-relieving cataplasm and effects of gaultherolin in prescriptions.
Ying LI ; Shou-Ying DU ; Yang LU ; Jie BAI ; Ying-Zi WANG ; Yue WANG ; Yu-Shu XING ; Wei XIAO
China Journal of Chinese Materia Medica 2013;38(16):2601-2604
OBJECTIVETo study transdermal absorption characteristics of eugenol in compound Nanxing pain-relieving cataplasm, and discuss the effect of gaultherolin on the transdermal absorption of the cataplasm.
METHODThe improved franz diffusing cell was adopted with hairless mice skins as transdermal carriers. The content of eugenol in receptor liquid, skins and cataplasm were analyzed by HPLC and compared with the cataplasm without gaultherolin.
RESULTThe penetration rates of eugenol of cataplasms with and without gaultherolin were 13.18 and 9.58 microg x cm(-2) x h(-1), with the retention amount in skins of (185.02 +/- 19.23) and (160.23 +/- 16.54) microg x g(-1) and the retention amount in cataplasms was (1.96 +/- 0.12) and (1.71 +/- 0.15) mg, respectively.
CONCLUSIONEugenol in compound Nanxing pain-relieving cataplasm has good pereutaoeous permeation. Gaultherolin in the cataplasm prescription can promote the absorption of eugenol.
Analgesics ; chemistry ; metabolism ; therapeutic use ; Animals ; Chemistry, Pharmaceutical ; methods ; Drugs, Chinese Herbal ; chemistry ; metabolism ; therapeutic use ; Mice ; Pain ; drug therapy ; Salicylates ; chemistry ; Skin ; metabolism ; Skin Absorption ; Time Factors
3.Effect of Triflusal on Primary Vascular Dysregulation Compared with Aspirin: A Double-Blind, Randomized, Crossover Trial.
Sanghoon SHIN ; Kwang Joon KIM ; In Jeong CHO ; Geu Ru HONG ; Yangsoo JANG ; Namsik CHUNG ; Young Min RAH ; Hyuk Jae CHANG
Yonsei Medical Journal 2015;56(5):1227-1234
PURPOSE: Primary vascular dysregulation (PVD) is a condition in which the response to cold temperature or external stimuli is abnormal. We investigated whether triflusal use results in amelioration of PVD symptoms and improvement of several related parameters compared with aspirin. MATERIALS AND METHODS: Eighty-eight PVD patients (54% female, 56+/-8 years) were randomly selected to receive either triflusal (300 mg, b.i.d.) or aspirin (150 mg, b.i.d.) for a period of 6 weeks followed by crossover. PVD was defined as both red-blood-cell standstill in video-assisted microscopic capillaroscopy during cold stimulation using carbon dioxide gas and a score of more than 7 points in a validated questionnaire. Efficacy of treatment was assessed by 1) cold intolerance symptom severity (CISS) score, 2) finger Doppler indices, and 3) indocyanine green perfusion imaging. RESULTS: The use of triflusal resulted in a greater improvement in CISS score (44.5+/-18.4 vs. 51.9+/-16.2; p<0.001) and in mean radial peak systolic velocity (69.8+/-17.2 vs. 66.1+/-16.4; p=0.011) compared to aspirin. Furthermore, significant differences were also observed in perfusion rates on indocyanine green perfusion imaging between triflusal and aspirin (45.6+/-25.8 vs. 51.6+/-26.9; p=0.020). CONCLUSION: Triflusal was more effective and demonstrated a more consistent impact on the improvement of symptoms and blood flow in patients with PVD than aspirin.
Adult
;
Aspirin/*therapeutic use
;
Cardiovascular Diseases/*drug therapy
;
Cross-Over Studies
;
Double-Blind Method
;
Female
;
Humans
;
Indocyanine Green
;
Male
;
Middle Aged
;
Perfusion Imaging
;
Platelet Aggregation Inhibitors/*therapeutic use
;
Recurrence
;
Salicylates/*therapeutic use
;
Treatment Outcome
4.Synthesis of 2-hydroxyl-5-butyramidobenzoic acid and its effect on acetic acid-induced colitis in rats.
Rui-cai SHI ; Jian-feng XING ; Zhao-guo LIU ; Zhi-zhao YUAN ; San-qi ZHANG ; Xiao-li BIAN ; Ai-guo ZENG
Journal of Southern Medical University 2009;29(9):1843-1845
OBJECTIVETo study the method for synthesis of 2-hydroxyl-5- butyramidobenzoic acid and test its effect on acetic acid-induced colitis in rats.
METHODS2-hydroxyl-5-butyramidobenzoic acid was synthesized from 5-aminosalicylic acid and butyric acid by amidation, esterification and hydrolization. The effect of 2-hydroxyl-5-butyramidobenzoic acid on acetic acid enema-induced colitis in rats was investigated.
RESULTSThe structure of 2-hydroxyl-5-butyramidobenzoic acid was identified by IR and 1H-NMR. After treatment with acetic acid, the colon mucosal damage index (CMDI), fecal occult blood (OB) test, and activity of myelperoxidase (MPO) increased significantly in the rats as compared to the control levels. 2-hydroxyl-5- butyramidobenzoic acid obviously reduced the CMDI and OB, and reduced the level of MPO in the rats with colitis.
CONCLUSIONThe synthesis of 2-hydroxyl-5-butyramidobenzoic acid requires only mild conditions with simple procedures, and the synthesized 2-hydroxyl-5-butyramidobenzoic acid shows obvious therapeutic effects on mucosal damage of in rats with acetic acid-induced colitis.
Acetic Acid ; Aminobenzoates ; chemical synthesis ; chemistry ; pharmacology ; therapeutic use ; Animals ; Colitis, Ulcerative ; chemically induced ; drug therapy ; Male ; Protective Agents ; chemical synthesis ; pharmacology ; therapeutic use ; Rats ; Rats, Sprague-Dawley ; Salicylates
5.A meta-analysis of salicylates for type 2 diabetes mellitus.
Fang FANG ; Yu LU ; De-lin MA ; Ting-ting DU ; Shi-ying SHAO ; Xue-feng YU
Journal of Huazhong University of Science and Technology (Medical Sciences) 2013;33(1):1-14
The aim of this study was to assess the effects and safety of salicylates on type 2 diabetes mellitus (T2DM). We searched six databases (Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CBM, CNKI and VIP) for all randomized controlled trials (RCTs) and self-control studies which investigated the effects of salicylates on T2DM. We included 34 RCTs and 17 self-control studies involving 13 464 patients with T2DM. It was demonstrated that salicylates had obvious effects on several parameters for patients with T2DM. (1) Any dose of salicylates could significantly reduce HbA1c level [mean difference (MD) -0.39%; 95% CI -0.47 to -0.32] in RCTs, but only high doses of salicylates (≥3000 mg/day) could effectively reduce fasting plasma glucose (FPG) level [standardized mean difference (SMD) -1.05; 95% CI -1.47 to -0.62] for patients with T2DM in both RCTs and self-control studies. Furthermore, high doses of salicylates could also increase plasma fasting insulin level (MD 12.20 mU/L; 95% CI 3.33 to 21.07); (2) In both RCTs and self-control studies, high doses of salicylates could significantly reduce plasma triglycerides concentration. The results for RCTs were MD -0.44 mmol/L, 95% CI -0.71 to -0.18, and those for self-control studies were 227±29 mg/dL (pre-treatment) and 117±8 mg/dL (post-treatment) (P=0.009); (3) All trials which reported cardiovascular events were RCTs using low doses (<1000 mg/day) of salicylates, and it was revealed that aspirin could significantly reduce the risk of myocardial infarction (OR 0.73; 95% CI 0.57 to 0.92); (4) Two RCTs and two self-control studies with ≥3000 mg/day salicylates reported adverse effects, and the overall effects were mild, and tinnitus occurred most frequently. No evidence of gastrointestinal bleeding was found in all these studies. In conclusion, from our systematic review, the anti-diabetic effect of salicylates is in a dose-dependent manner. High doses of salicylates may have beneficial effects on reducing FPG, HbA1c level and increasing fasting insulin concentration, and may also have some positive effects on lipidemia and inflammation-associated parameters for patients with T2DM, without serious adverse effects.
Anti-Inflammatory Agents, Non-Steroidal
;
therapeutic use
;
Cardiovascular Diseases
;
mortality
;
prevention & control
;
Comorbidity
;
Diabetes Mellitus, Type 2
;
drug therapy
;
mortality
;
Humans
;
Incidence
;
Randomized Controlled Trials as Topic
;
statistics & numerical data
;
Risk Factors
;
Salicylates
;
therapeutic use
;
Survival Rate
;
Treatment Outcome